Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.01.010
Miah Roney, Mohd Fadhlizil Fasihi Mohd Aluwi
The use of in-silico research in drug development is growing. Aspects of drug discovery and development, such as virtual ligand screening and profiling, target and lead finding, and compound library creation, are simulated by computational approaches. Databases, pharmacophores, homology models, quantitative structure–activity connections, machine learning, data mining, network analysis tools, and computer-based data analysis tools are examples of in-silico techniques. These techniques are mostly applied in conjunction with the production of in vitro data to build models that facilitate the identification and refinement of new compounds by providing insight into their features related to absorption, distribution, metabolism, and excretion.
{"title":"The importance of in-silico studies in drug discovery","authors":"Miah Roney, Mohd Fadhlizil Fasihi Mohd Aluwi","doi":"10.1016/j.ipha.2024.01.010","DOIUrl":"10.1016/j.ipha.2024.01.010","url":null,"abstract":"<div><p>The use of in-silico research in drug development is growing. Aspects of drug discovery and development, such as virtual ligand screening and profiling, target and lead finding, and compound library creation, are simulated by computational approaches. Databases, pharmacophores, homology models, quantitative structure–activity connections, machine learning, data mining, network analysis tools, and computer-based data analysis tools are examples of in-silico techniques. These techniques are mostly applied in conjunction with the production of in vitro data to build models that facilitate the identification and refinement of new compounds by providing insight into their features related to absorption, distribution, metabolism, and excretion.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 578-579"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000200/pdfft?md5=a7867f2e1e88920b4714446ae3598312&pid=1-s2.0-S2949866X24000200-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.05.004
Cowhide collagen hydrolysates (CCHs) are peptides and amino acids obtained from the partial hydrolysis of collagen. These have numerous potential applications in the food, biomedical, and pharmaceutical industries. The study analyzed the physicochemical, antioxidant, and anti-atherosclerosis properties of collagen hydrolysates (CCHs) from cowhide using in silico methods. Proteins were identified in silico based on their molecular weights and origin from the protein database (UniProtKB). Using bioinformatics tools, numerous physicochemical properties (toxicity and amino acid composition) were determined. The identified proteins were subsequently subjected to an in silico enzymatic hydrolysis using pepsin, thermolysin, and proteinase K. The peptides obtained were characterized. Molecular docking was conducted between the peptides generated in silico and the three target enzymes (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) reductase, cyclooxygenase-2, and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase). Two cowhide collagens were identified, F1MJQ6 and G3MZI7, with molecular weights of 172,076 and 184,867 Da, respectively. A compositional analysis of F1MJQ6 and G3MZI7 revealed the significant presence of glycine residues at 25% and 23%, and proline residues at 16% and 18%, respectively. The G3MZI7 and F1MJQ6 proteins exhibited a high concentration of both essential and semi-essential amino acids. The molecular docking results indicate that the antioxidant peptides ADF, PHF, and LW (novel potential anti-atherosclerosis peptides released by enzymatic hydrolysis with pepsin, thermolysin, and proteinase K) are the most promising candidates for further development as inhibitors of HMG-CoA reductase, cyclo-oxygenase-2, and NADPH oxidase. In silico analysis revealed that cowhide collagen hydrolysates exhibited particularly significant antioxidant and anti-atherosclerosis properties.
{"title":"Bioactive peptides derived from the enzymatic hydrolysis of cowhide collagen for the potential treatment of atherosclerosis: A computational approach","authors":"","doi":"10.1016/j.ipha.2024.05.004","DOIUrl":"10.1016/j.ipha.2024.05.004","url":null,"abstract":"<div><p>Cowhide collagen hydrolysates (CCHs) are peptides and amino acids obtained from the partial hydrolysis of collagen. These have numerous potential applications in the food, biomedical, and pharmaceutical industries. The study analyzed the physicochemical, antioxidant, and anti-atherosclerosis properties of collagen hydrolysates (CCHs) from cowhide using <em>in silico</em> methods. Proteins were identified <em>in silico</em> based on their molecular weights and origin from the protein database (UniProtKB). Using bioinformatics tools, numerous physicochemical properties (toxicity and amino acid composition) were determined. The identified proteins were subsequently subjected to an <em>in silico</em> enzymatic hydrolysis using pepsin, thermolysin, and proteinase K. The peptides obtained were characterized. Molecular docking was conducted between the peptides generated <em>in silico</em> and the three target enzymes (3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) reductase, cyclooxygenase-2, and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase). Two cowhide collagens were identified, F1MJQ6 and G3MZI7, with molecular weights of 172,076 and 184,867 Da, respectively. A compositional analysis of F1MJQ6 and G3MZI7 revealed the significant presence of glycine residues at 25% and 23%, and proline residues at 16% and 18%, respectively. The G3MZI7 and F1MJQ6 proteins exhibited a high concentration of both essential and semi-essential amino acids. The molecular docking results indicate that the antioxidant peptides ADF, PHF, and LW (novel potential anti-atherosclerosis peptides released by enzymatic hydrolysis with pepsin, thermolysin, and proteinase K) are the most promising candidates for further development as inhibitors of HMG-CoA reductase, cyclo-oxygenase-2, and NADPH oxidase. <em>In silico</em> analysis revealed that cowhide collagen hydrolysates exhibited particularly significant antioxidant and anti-atherosclerosis properties.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 456-466"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000649/pdfft?md5=cc419310465d774ff59c2aac885be063&pid=1-s2.0-S2949866X24000649-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141037354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2023.12.004
Abduljelil Ajala , Adamu Uzairu , Gideon A. Shallangwa , Stephen E Abechi , Abdullahi Bello Umar , Ibrahim A Abdulganiyyu , Ramith Ramu , Naveen Kumar
Alzheimer's disease (AD) is a brain disorder that is known to be one of the deadliest diseases affecting humanity, especially adults from the age of sixty (60) years and above. It mostly affects thinking ability, behaviour and social skills, eventually, AD causes the brain to shrink and brain cells to die. To curb the menace of this disease, virtual screening of potent, non-toxic hybrid natural therapeutic inhibitors was performed on some inhibitors of AD. We performed simulations on the screened compounds and predicted their druggability. A model with satisfactory statistical properties was developed in this study. The ligands underwent molecular docking, C-19 exhibited the highest docked score of −12.8 kcal/mol against the target, while the referenced compound (harmine) indicated the lowest docked score of −8.2 kcal/mol. The docked complex was validated using molecular dynamic simulations. Trajectory plots of C-19 were obtained and found to be stable. C-19 was stable during the 100 ns intervals which implies that the compounds were better than the referenced compound. In addition, ADMET has demonstrated that these ligands have good pharmacokinetic properties. All the evaluations were more comprehensive and beneficial to researchers and the medical community as outstanding results were obtained.
{"title":"QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis","authors":"Abduljelil Ajala , Adamu Uzairu , Gideon A. Shallangwa , Stephen E Abechi , Abdullahi Bello Umar , Ibrahim A Abdulganiyyu , Ramith Ramu , Naveen Kumar","doi":"10.1016/j.ipha.2023.12.004","DOIUrl":"10.1016/j.ipha.2023.12.004","url":null,"abstract":"<div><p>Alzheimer's disease (AD) is a brain disorder that is known to be one of the deadliest diseases affecting humanity, especially adults from the age of sixty (60) years and above. It mostly affects thinking ability, behaviour and social skills, eventually, AD causes the brain to shrink and brain cells to die. To curb the menace of this disease, virtual screening of potent, non-toxic hybrid natural therapeutic inhibitors was performed on some inhibitors of AD. We performed simulations on the screened compounds and predicted their druggability. A model with satisfactory statistical properties was developed in this study. The ligands underwent molecular docking, C-19 exhibited the highest docked score of −12.8 kcal/mol against the target, while the referenced compound (harmine) indicated the lowest docked score of −8.2 kcal/mol. The docked complex was validated using molecular dynamic simulations. Trajectory plots of C-19 were obtained and found to be stable. C-19 was stable during the 100 ns intervals which implies that the compounds were better than the referenced compound. In addition, ADMET has demonstrated that these ligands have good pharmacokinetic properties. All the evaluations were more comprehensive and beneficial to researchers and the medical community as outstanding results were obtained.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 505-515"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001302/pdfft?md5=92629a1bf2eae34b48dd7013a0e45788&pid=1-s2.0-S2949866X23001302-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.05.009
Emyr Hiago Bellaver , Ingrid Militão da Costa , Eduarda Eliza Redin , Liziane Schittler Moroni , Aniela Pinto Kempka
The increasing quest for therapeutic alternatives in treating non-communicable chronic diseases like obesity has propelled research into bioactive peptides, with a particular focus on milk due to its rich protein composition and associated health benefits. Milk fermentation, a traditional process in dairy production, enhances the bioactivity of peptides, broadening their potential therapeutic uses. This study investigated the anti-obesity potential of peptides from bovine milk fermented by Lacticaseibacillus casei LBC 237, identifying 143 peptides, notably LGPV and EVPMP. In silico analyses revealed that LGPV and EVPMP biopeptides exhibited significant interactions with target proteins, employing various molecular interactions such as Van der Waals forces, hydrogen bonds, and electrostatic interactions. These peptides shared common binding sites in some enzymes, suggesting a similar mode of interaction between molecule and target protein, akin to key pharmaceuticals recommended for treating these pathologies. Furthermore, amino acid characteristics present in the peptides, including hydrophobic residues like Leucine, Glutamate, Valine, and Proline, proved essential for their bioactive and inhibitory activities. These findings highlight the potential of LGPV and EVPMP biopeptides as therapeutic agents in managing obesity and metabolic disorders. They provide important insights into their mechanisms of action, paving the way for future research to apply them practically in preventing and treating metabolic conditions.
{"title":"The fermented milk can be a natural ally against obesity? Investigation of bovine milk fermentation by Lacticaseibacillus casei LBC 237, screening, and In silico predictions of bioactive peptides for obesity control","authors":"Emyr Hiago Bellaver , Ingrid Militão da Costa , Eduarda Eliza Redin , Liziane Schittler Moroni , Aniela Pinto Kempka","doi":"10.1016/j.ipha.2024.05.009","DOIUrl":"10.1016/j.ipha.2024.05.009","url":null,"abstract":"<div><p>The increasing quest for therapeutic alternatives in treating non-communicable chronic diseases like obesity has propelled research into bioactive peptides, with a particular focus on milk due to its rich protein composition and associated health benefits. Milk fermentation, a traditional process in dairy production, enhances the bioactivity of peptides, broadening their potential therapeutic uses. This study investigated the anti-obesity potential of peptides from bovine milk fermented by <em>Lacticaseibacillus casei</em> LBC 237, identifying 143 peptides, notably LGPV and EVPMP. <em>In silico</em> analyses revealed that LGPV and EVPMP biopeptides exhibited significant interactions with target proteins, employing various molecular interactions such as Van der Waals forces, hydrogen bonds, and electrostatic interactions. These peptides shared common binding sites in some enzymes, suggesting a similar mode of interaction between molecule and target protein, akin to key pharmaceuticals recommended for treating these pathologies. Furthermore, amino acid characteristics present in the peptides, including hydrophobic residues like Leucine, Glutamate, Valine, and Proline, proved essential for their bioactive and inhibitory activities. These findings highlight the potential of LGPV and EVPMP biopeptides as therapeutic agents in managing obesity and metabolic disorders. They provide important insights into their mechanisms of action, paving the way for future research to apply them practically in preventing and treating metabolic conditions.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 467-484"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000698/pdfft?md5=f1aaa04a5548fb0a283fe00c0055a356&pid=1-s2.0-S2949866X24000698-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141990557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2023.12.005
Breast cancer remains a significant global health concern, necessitating the exploration of novel preventive and therapeutic strategies. Dietary interventions have gained substantial attention due to their potential to modulate cancer risk and progression. Millets, a group of small-seeded grasses, have emerged as promising candidates in this regard, owing to their rich nutritional composition and diverse bioactive compounds. Among these bioactive compounds, phytate antinutrients have garnered considerable interest for their potential health benefits. This review aims to unravel the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer. Phytates are naturally occurring compounds present in various plant-based foods, including millets, and are known for their ability to chelate minerals and inhibit their bioavailability. However, recent research has shed light on the multifaceted properties of phytates, highlighting their potential as functional bioactive molecules. Phytates exhibit various anticancer properties, including “antioxidant, anti-inflammatory, and antiproliferative effects”, which have been shown to inhibit the growth and progression of breast cancer cells. Additionally, phytates have been reported to modulate key signaling pathways involved in cancer development, such as PI3K/Akt, MAPK, and NF-κB, thereby exerting their anticancer effects. Moreover, phytates demonstrate the potential to enhance the efficacy of conventional breast cancer treatments, such as chemotherapy and radiation therapy, while mitigating their adverse effects. Furthermore, the bioavailability and metabolism of phytates are complex processes influenced by factors such as food processing, gut microbiota composition, and genetic variations. Understanding these intricacies is crucial for harnessing the full potential of phytates in breast cancer prevention and treatment. In conclusion, this review provides a comprehensive overview of the intricate roles of phytate antinutrients in millets and their therapeutic implications in breast cancer. The findings suggest that millets, as a rich source of phytates, could be incorporated into dietary strategies to reduce breast cancer risk and complement existing therapeutic approaches. However, further research is warranted to elucidate the precise mechanisms of action, optimal dosage, and potential synergistic effects with other bioactive compounds. The information that is given here is supported by accurate facts and arguments that have undergone rigorous scrutiny.
{"title":"Unveiling the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer","authors":"","doi":"10.1016/j.ipha.2023.12.005","DOIUrl":"10.1016/j.ipha.2023.12.005","url":null,"abstract":"<div><p>Breast cancer remains a significant global health concern, necessitating the exploration of novel preventive and therapeutic strategies. Dietary interventions have gained substantial attention due to their potential to modulate cancer risk and progression. Millets, a group of small-seeded grasses, have emerged as promising candidates in this regard, owing to their rich nutritional composition and diverse bioactive compounds. Among these bioactive compounds, phytate antinutrients have garnered considerable interest for their potential health benefits. This review aims to unravel the intricacies of phytate antinutrients in millets and their therapeutic implications in breast cancer. Phytates are naturally occurring compounds present in various plant-based foods, including millets, and are known for their ability to chelate minerals and inhibit their bioavailability. However, recent research has shed light on the multifaceted properties of phytates, highlighting their potential as functional bioactive molecules. Phytates exhibit various anticancer properties, including “antioxidant, anti-inflammatory, and antiproliferative effects”, which have been shown to inhibit the growth and progression of breast cancer cells. Additionally, phytates have been reported to modulate key signaling pathways involved in cancer development, such as PI3K/Akt, MAPK, and NF-κB, thereby exerting their anticancer effects. Moreover, phytates demonstrate the potential to enhance the efficacy of conventional breast cancer treatments, such as chemotherapy and radiation therapy, while mitigating their adverse effects. Furthermore, the bioavailability and metabolism of phytates are complex processes influenced by factors such as food processing, gut microbiota composition, and genetic variations. Understanding these intricacies is crucial for harnessing the full potential of phytates in breast cancer prevention and treatment. In conclusion, this review provides a comprehensive overview of the intricate roles of phytate antinutrients in millets and their therapeutic implications in breast cancer. The findings suggest that millets, as a rich source of phytates, could be incorporated into dietary strategies to reduce breast cancer risk and complement existing therapeutic approaches. However, further research is warranted to elucidate the precise mechanisms of action, optimal dosage, and potential synergistic effects with other bioactive compounds. The information that is given here is supported by accurate facts and arguments that have undergone rigorous scrutiny.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 516-527"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001314/pdfft?md5=7a60ada6a931260ba11551212d20f20c&pid=1-s2.0-S2949866X23001314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139190766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.05.003
Background
The COVID-19 pandemic significantly affects patients with RA and other rheumatic diseases. Our study aims to explore the factors associated with COVID-19-related fatality among Rheumatoid Arthritis (RA) patients, especially immunomodulatory therapies, using the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Methods
Reportes from FAERS were extracted from February 2020 to September 2022, and uesd for this cross-sectional analysis. The investigative outcome was COVID-19-related death. Age, sex, region, event date, and immunomodulatory medications classies were included as co-variates in multivariable logistic regression. In view of the different targeting and affinity of individual JAKi, Tofacitinib, Upadacitinib and Baricitinib was respectively analyzed.
Results
In all, 3808 cases (mean age 58.85 years, 82.8% female), 267 (7.0%) died. JAKi therapies (41.2%), followed by TNFi (37.7%), IL-1i (12.2%), IL-6i (4.1%) and Anti-CD20 (3%) were reported. Risk factors associated with COVID-19-related death in RA patients were age (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05–1.08; p < 0.01), male sex (1.71, 1.26–2.33; p = 0.01) and anti-CD20 therapies (5.05; 1.40–18.19; p = 0.013). With TNFi conference, anti-CD20 was still a risk predictor (4.29; 2.39–7.70; p < 0.01). Other DMARDs except for anti-CD20, did not confer a significant association with mortality, compared with csDMARDs or TNFi. Individual JAKi showed no obvious difference in the risk of death, compared with csDMARDs or TNFis.
Conclusions
Conclusions Using FAERS open access data for risk prediction of death, anti-CD20 therapies were recognized as a risk factor for COVID-19-related fatalities among RA patients, other immunomodulatory therapies were not associated with mortality, compared with csDMARDs or TNFis.
{"title":"Association of immunomodulatory therapies with COVID-19 mortality in rheumatoid arthritis: An analysis of the FDA adverse event reporting system","authors":"","doi":"10.1016/j.ipha.2024.05.003","DOIUrl":"10.1016/j.ipha.2024.05.003","url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic significantly affects patients with RA and other rheumatic diseases. Our study aims to explore the factors associated with COVID-19-related fatality among Rheumatoid Arthritis (RA) patients, especially immunomodulatory therapies, using the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).</p></div><div><h3>Methods</h3><p>Reportes from FAERS were extracted from February 2020 to September 2022, and uesd for this cross-sectional analysis. The investigative outcome was COVID-19-related death. Age, sex, region, event date, and immunomodulatory medications classies were included as co-variates in multivariable logistic regression. In view of the different targeting and affinity of individual JAKi, Tofacitinib, Upadacitinib and Baricitinib was respectively analyzed.</p></div><div><h3>Results</h3><p>In all, 3808 cases (mean age 58.85 years, 82.8% female), 267 (7.0%) died. JAKi therapies (41.2%), followed by TNFi (37.7%), IL-1i (12.2%), IL-6i (4.1%) and Anti-CD20 (3%) were reported. Risk factors associated with COVID-19-related death in RA patients were age (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05–1.08; <em>p</em> < 0.01), male sex (1.71, 1.26–2.33; <em>p</em> = 0.01) and anti-CD20 therapies (5.05; 1.40–18.19; <em>p</em> = 0.013). With TNFi conference, anti-CD20 was still a risk predictor (4.29; 2.39–7.70; <em>p</em> < 0.01). Other DMARDs except for anti-CD20, did not confer a significant association with mortality, compared with csDMARDs or TNFi. Individual JAKi showed no obvious difference in the risk of death, compared with csDMARDs or TNFis.</p></div><div><h3>Conclusions</h3><p>Conclusions Using FAERS open access data for risk prediction of death, anti-CD20 therapies were recognized as a risk factor for COVID-19-related fatalities among RA patients, other immunomodulatory therapies were not associated with mortality, compared with csDMARDs or TNFis.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 451-455"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X2400056X/pdfft?md5=6bd80a6185e4a935d2ab2cce768c6ee4&pid=1-s2.0-S2949866X2400056X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141047696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.01.001
This study focuses on the development of a liposomal preparation for the targeted delivery of Telmisartan in the context of breast cancer treatment. Telmisartan, a pharmaceutical agent with potential anticancer properties, has been encapsulated within liposomes, lipid-based vesicles known for their capacity to enhance drug delivery and improve therapeutic outcomes. The formulation and characterization of Telmisartan-loaded liposomes were conducted, evaluating factors such as size, shape, and drug release profiles. The findings demonstrate that the liposomal preparation effectively encapsulates Telmisartan, maintaining its pharmacological properties. The development of such liposomal formulations holds promise for advancing breast cancer therapies, offering the potential for enhanced treatment efficacy and reduced side effects. This research contributes to the ongoing efforts to explore innovative drug delivery strategies in the realm of breast cancer treatment. Breast cancer is a pervasive and challenging malignancy affecting women worldwide. In the quest for more effective and targeted treatment approaches, the development of liposomal preparations for delivering therapeutic agents to breast cancer cells has emerged as a promising avenue. Telmisartan, originally recognized for its antihypertensive properties, has been increasingly investigated for its potential anticancer effects. This study delves into the design and evaluation of a liposomal formulation for Telmisartan, aiming to enhance its therapeutic potential in breast cancer. The formulation process involved the encapsulation of Telmisartan within lipid-based liposomes, which are well-known for their ability to carry a variety of drugs, protect them from degradation, and enhance their selective delivery to tumor cells.
{"title":"Telmisartan-loaded liposomes: An innovative weapon against breast cancer","authors":"","doi":"10.1016/j.ipha.2024.01.001","DOIUrl":"10.1016/j.ipha.2024.01.001","url":null,"abstract":"<div><p>This study focuses on the development of a liposomal preparation for the targeted delivery of Telmisartan in the context of breast cancer treatment. Telmisartan, a pharmaceutical agent with potential anticancer properties, has been encapsulated within liposomes, lipid-based vesicles known for their capacity to enhance drug delivery and improve therapeutic outcomes. The formulation and characterization of Telmisartan-loaded liposomes were conducted, evaluating factors such as size, shape, and drug release profiles. The findings demonstrate that the liposomal preparation effectively encapsulates Telmisartan, maintaining its pharmacological properties. The development of such liposomal formulations holds promise for advancing breast cancer therapies, offering the potential for enhanced treatment efficacy and reduced side effects. This research contributes to the ongoing efforts to explore innovative drug delivery strategies in the realm of breast cancer treatment. Breast cancer is a pervasive and challenging malignancy affecting women worldwide. In the quest for more effective and targeted treatment approaches, the development of liposomal preparations for delivering therapeutic agents to breast cancer cells has emerged as a promising avenue. Telmisartan, originally recognized for its antihypertensive properties, has been increasingly investigated for its potential anticancer effects. This study delves into the design and evaluation of a liposomal formulation for Telmisartan, aiming to enhance its therapeutic potential in breast cancer. The formulation process involved the encapsulation of Telmisartan within lipid-based liposomes, which are well-known for their ability to carry a variety of drugs, protect them from degradation, and enhance their selective delivery to tumor cells.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 565-570"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000017/pdfft?md5=1596786390e538b379ae6753631be0ac&pid=1-s2.0-S2949866X24000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2023.12.007
The activity of Seborrheic dermatitis on the skin of children still remains of the dermatoses of male and female babies in the early days of their existence. Acalypha wilkesiana L have been employed by mothers to combat Seborrheic dermatitis, yet, the descriptors responsible for such activity as well as the nonbonding interactions between the selected phytochemicals and stearoyl-CoA desaturase has not been explored. The studied compounds were optimized using Spartan’14 software as well as molecular operating environments (MOE) for docking, Cytoscape software for compound-protein interaction network, Gromacs for molecular dynamic simulation as well ADMETSar for pharmacokinetics studies. The selected compounds proved to have anti-stearoyl-CoA desaturase properties via the calculated descriptors obtained from the chemical compounds obtained from Acalypha wilkesiana L as well as from the result from molecular modeling studies. The Pharmacokinetics results were observed and reported appropriately.
儿童皮肤上的脂溢性皮炎仍然是男女婴儿出生初期的皮肤病之一。母亲们一直在使用 Acalypha wilkesiana L 来防治脂溢性皮炎,但尚未探索导致这种活性的描述因子以及所选植物化学物质与硬脂酰-CoA 去饱和酶之间的非键相互作用。研究人员使用 Spartan'14 软件和分子操作环境(MOE)对所研究的化合物进行了优化对接,使用 Cytoscape 软件建立了化合物-蛋白质相互作用网络,使用 Gromacs 进行了分子动力学模拟,并使用 ADMETSar 进行了药代动力学研究。通过计算从 Acalypha wilkesiana L 中获得的化合物的描述符以及分子建模研究的结果,证明所选化合物具有抗硬脂酰-CoA 去饱和酶的特性。观察并适当报告了药代动力学结果。
{"title":"Acalypha wilkesiana L - A potential anti-stearoyl-CoA desaturase agent: Insilico and network pharmacology studies","authors":"","doi":"10.1016/j.ipha.2023.12.007","DOIUrl":"10.1016/j.ipha.2023.12.007","url":null,"abstract":"<div><p>The activity of Seborrheic dermatitis on the skin of children still remains of the dermatoses of male and female babies in the early days of their existence. <em>Acalypha wilkesiana</em> L have been employed by mothers to combat Seborrheic dermatitis, yet, the descriptors responsible for such activity as well as the nonbonding interactions between the selected phytochemicals and stearoyl-CoA desaturase has not been explored. The studied compounds were optimized using Spartan’14 software as well as molecular operating environments (MOE) for docking, Cytoscape software for compound-protein interaction network, Gromacs for molecular dynamic simulation as well ADMETSar for pharmacokinetics studies. The selected compounds proved to have anti-stearoyl-CoA desaturase properties via the calculated descriptors obtained from the chemical compounds obtained from <em>Acalypha wilkesiana</em> L as well as from the result from molecular modeling studies. The Pharmacokinetics results were observed and reported appropriately.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 540-553"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23001338/pdfft?md5=bf21b043b1b223a595481f0223babd84&pid=1-s2.0-S2949866X23001338-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139191506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2024.01.011
The field of oral drug delivery has witnessed significant advancements, with a focus on developing innovative formulations to address challenges associated with traditional dosage forms, especially for patients with difficulties in swallowing. Fast Dissolving Tablets (FDTs) have emerged as a promising class of tablets designed to rapidly disintegrate or dissolve in saliva, providing a convenient and patient-friendly alternative for various populations.
This article explores the unique properties, advantages, and potential applications of FDTs, emphasizing their role in overcoming challenges posed by conventional oral drug delivery systems. FDTs offer rapid dissolution within 15-120 seconds in the buccal cavity, facilitating direct absorption through the buccal mucosa and ensuring quick therapeutic effects. This characteristic proves particularly beneficial for individuals facing swallowing challenges, such as pediatric and geriatric patients, or those with conditions like dysphagia.
Recognizing the significance of FDTs, the European Pharmacopoeia (EP) has officially recognized them as “oral dissolving tablets," highlighting their acceptance in both academic and industrial settings. The article delves into the anatomical and physiological characteristics of the oral cavity, shedding light on the buccal epithelium, oral mucosa vascularization, and salivary flow, which play crucial roles in drug absorption.
The ideal features of FDTs include rapid dissolution or disintegration, high drug load capacity, masking of bitter taste, positive mouth feel, ease of transport, and reduced sensitivity to environmental factors. The advantages of FDTs extend to their administration for patients unable to swallow, convenient treatment for bedridden and mobile patients, enhanced mouth feel and taste masking, ease of administration, and precise dosing.
Despite their advantages, FDTs come with limitations, including issues related to mechanical strength, hygroscopic nature, brittleness, and challenges with bitter drugs or unpleasant odors. Overcoming these challenges requires a careful formulation approach to balance rapid disintegration with mechanical strength and taste masking.
The article also discusses the salient characteristics of Fast Dissolving Dosage Forms (FDDDS) and various techniques for preparing FDTs, such as freeze-drying, tablet molding, and spray drying. Additionally, it explores the role of non-invasive drug delivery systems in addressing pharmaceutical industry needs, including improving drug half-life, solubility/stability, and bioavailability.
{"title":"Advancing oral drug delivery: The science of fast dissolving tablets (FDTs)","authors":"","doi":"10.1016/j.ipha.2024.01.011","DOIUrl":"10.1016/j.ipha.2024.01.011","url":null,"abstract":"<div><p>The field of oral drug delivery has witnessed significant advancements, with a focus on developing innovative formulations to address challenges associated with traditional dosage forms, especially for patients with difficulties in swallowing. Fast Dissolving Tablets (FDTs) have emerged as a promising class of tablets designed to rapidly disintegrate or dissolve in saliva, providing a convenient and patient-friendly alternative for various populations.</p><p>This article explores the unique properties, advantages, and potential applications of FDTs, emphasizing their role in overcoming challenges posed by conventional oral drug delivery systems. FDTs offer rapid dissolution within 15-120 seconds in the buccal cavity, facilitating direct absorption through the buccal mucosa and ensuring quick therapeutic effects. This characteristic proves particularly beneficial for individuals facing swallowing challenges, such as pediatric and geriatric patients, or those with conditions like dysphagia.</p><p>Recognizing the significance of FDTs, the European Pharmacopoeia (EP) has officially recognized them as “oral dissolving tablets,\" highlighting their acceptance in both academic and industrial settings. The article delves into the anatomical and physiological characteristics of the oral cavity, shedding light on the buccal epithelium, oral mucosa vascularization, and salivary flow, which play crucial roles in drug absorption.</p><p>The ideal features of FDTs include rapid dissolution or disintegration, high drug load capacity, masking of bitter taste, positive mouth feel, ease of transport, and reduced sensitivity to environmental factors. The advantages of FDTs extend to their administration for patients unable to swallow, convenient treatment for bedridden and mobile patients, enhanced mouth feel and taste masking, ease of administration, and precise dosing.</p><p>Despite their advantages, FDTs come with limitations, including issues related to mechanical strength, hygroscopic nature, brittleness, and challenges with bitter drugs or unpleasant odors. Overcoming these challenges requires a careful formulation approach to balance rapid disintegration with mechanical strength and taste masking.</p><p>The article also discusses the salient characteristics of Fast Dissolving Dosage Forms (FDDDS) and various techniques for preparing FDTs, such as freeze-drying, tablet molding, and spray drying. Additionally, it explores the role of non-invasive drug delivery systems in addressing pharmaceutical industry needs, including improving drug half-life, solubility/stability, and bioavailability.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 580-587"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X24000212/pdfft?md5=e5cec6d258d3bad65a1e92c82c1b4b2c&pid=1-s2.0-S2949866X24000212-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139874102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/j.ipha.2023.11.006
The murrcidae gastropod operculum has many therapeutic uses in ayurveda, including treating cancer, gastric, hepatic, cardiovascular, and immunological disorders. Antibacterial, cell reinforcement, FTIR, and mass spectrum datas were used to identify important functional groups and chemical constituents in Chicoreus ramosus operculum concentrate. At 100 mg/L, the operculum extract showed stronger inhibitory movement (125 mm) against Bacillus subtilis and less (08 mm) against Staphylococcus aureus. Operculum extract's biochemical composition, total antioxidant properties, protein denaturation, metal chelation movement, all-out cell reinforcement action, and anti-diabetic action were 85.71%, 80.98%, 32.03%, and 76.47% at 1000 μg/mL concentration. The operculum remove FTIR showed nine significant groups, including amines, esters, and fragrant mixtures. 11 dynamic mixtures from GC–MS analysis of operculum rough concentrate. These bioactive fractions interacted with IL 23 in molecular docking experiments. Androst-1-en-3-one, Bis (2-ethylhexyl) phthalate, and 3-Methoxy-2,4,5-trifluorobenzoic acid had the highest docking scores and target protein receptor interactions. −11.9 kcal/mol, −08.6 kcal/mol and −7.7 kcal/mol are the maximum scores. These compounds are therapeutic and antimicrobial. These bioactive compounds in operculum extracts allow C. ramosus to be used in conventional medicine and may lead to the development of new drugs.
{"title":"Nutritional composition, antioxidant properties, and molecular docking strategy of muricidae operculum (Chicoreus ramosus)","authors":"","doi":"10.1016/j.ipha.2023.11.006","DOIUrl":"10.1016/j.ipha.2023.11.006","url":null,"abstract":"<div><p>The murrcidae gastropod operculum has many therapeutic uses in ayurveda, including treating cancer, gastric, hepatic, cardiovascular, and immunological disorders. Antibacterial, cell reinforcement, FTIR, and mass spectrum datas were used to identify important functional groups and chemical constituents in <em>Chicoreus ramosus</em> operculum concentrate. At 100 mg/L, the operculum extract showed stronger inhibitory movement (125 mm) against <em>Bacillus subtilis</em> and less (08 mm) against <em>Staphylococcus aureus</em>. Operculum extract's biochemical composition, total antioxidant properties, protein denaturation, metal chelation movement, all-out cell reinforcement action, and anti-diabetic action were 85.71%, 80.98%, 32.03%, and 76.47% at 1000 μg/mL concentration. The operculum remove FTIR showed nine significant groups, including amines, esters, and fragrant mixtures. 11 dynamic mixtures from GC–MS analysis of operculum rough concentrate. These bioactive fractions interacted with IL 23 in molecular docking experiments. Androst-1-en-3-one, Bis (2-ethylhexyl) phthalate, and 3-Methoxy-2,4,5-trifluorobenzoic acid had the highest docking scores and target protein receptor interactions. −11.9 kcal/mol, −08.6 kcal/mol and −7.7 kcal/mol are the maximum scores. These compounds are therapeutic and antimicrobial. These bioactive compounds in operculum extracts allow <em>C. ramosus</em> to be used in conventional medicine and may lead to the development of new drugs.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 4","pages":"Pages 485-494"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X2300120X/pdfft?md5=f6d95fc4786d937e192d5d0daebbc96f&pid=1-s2.0-S2949866X2300120X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}